Pharma Focus Asia

Advanced Accelerator Applications Plans to Build Second US Manufacturing Site in Indianapolis

Introduction:

Advanced Accelerator Applications plans to build a new manufacturing facility for currently approved therapy and pipeline drug candidates in Indianapolis. The expansion would be the second US manufacturing site for targeted radioLigand therapy.

Features:

The new manufacturing facility designed with an area covering 50,000 square feet will produce targeted radioligand drugs which are used in the treatment of cancer.

The new facilities will include advanced manufacturing technologies; following the latest innovations in radiopharmaceutical production. The production facility is intended to be built with highest quality standards of safe and efficient operations. New construction is intended to support near and long-term manufacturing capacity planning for AAA’s marketed products and for clinical supply.

The new manufacturing facility is expected to complete the construction and start its initial operations by 2023.

Specifications:

NameAdvanced Accelerator Applications
TypeNew Facility
Year2023
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference